IMSC - .999 Another significant win for them.
Implant Sciences Explosives Trace Detection Equipment to Be Deployed at the Summit of the Americas
WILMINGTON, MA, Apr 10, 2012 (MARKETWIRE via COMTEX) -- Implant Sciences Corporation (otcqb:IMSC) (pinksheets:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that the Colombian National Police has selected Implant Sciences explosives trace detection equipment as part of the security plan for the Summit of the Americas. Both the Quantum Sniffer(TM) QS-H150 handheld explosives trace detectors and the Quantum Sniffer(TM) QS-B220 benchtop narcotics and explosives trace detectors will be used at the Sixth Summit of the Americas, where 34 heads of state and government of the Americas will convene in Cartagena, Colombia on April 14 and 15, 2012.
Implant Sciences systems will be deployed at entry checkpoints as the primary explosives screening mechanism for people, bags, and briefcases in a layered security environment.
The Summit of the Americas are institutionalized gatherings of the heads of state and government of the Western Hemisphere where leaders discuss common policy issues, affirm shared values and commit to concerted actions at the national and regional level to address continuing and new challenges faced in the Americas.
"I appreciate the effort that Implant Sciences and their local representatives have put into making it possible for us to use the QS-H150 and QS-B220 during the Summit of the Americas," commented Mayor General Jose Roberto Leon Riano, Subdirector General of the Colombian National Police. "It is very encouraging to see such cooperation in ensuring a safe and peaceful event, and I look forward to working with them in the future."
Implant Sciences President and CEO Glenn D. Bolduc added, "Our equipment has been selected to provide trace detection for the most important political summit of our hemisphere because of its proven performance in a wide range of applications. We are working closely with the Colombian National Police on delivery, set up and implementation of our handheld and benchtop units. This is an opportunity for us to not only provide security at this critical event, but also to receive additional exposure for our products in front of key governmental decision makers from South, Central, and North America."
About the Quantum Sniffer(TM) QS-H150 The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.
About the Quantum Sniffer(TM) QS-B220 The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.
About Implant Sciences Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com .
Safe Harbor Statement This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
Investor Contact:
Laurel Moody
646-810-0608
Email Contact
